For clinicians
Treatment Program for Treatment-Resistant Depression
- Covered by your insurance (policy-dependent)
- Immediate start, no waiting lists
For clinicians
Magnolia Therapy offers two specialist treatment programmes for patients with treatment-resistant depressive disorder (TRD):
- The programme with the possibility of racemic ketamine (intramuscular)
- The programme with esketamine nasal spray (Spravato®)
Both trajectories are intended for patients whose previous treatment steps have had insufficient effect.
The treatment is delivered by a multidisciplinary team consisting of psychiatrists, physicians, psychologists, and nurses. Pharmacological interventions are integrated within a structured psychotherapeutic treatment plan, with continuous monitoring and multidisciplinary consultation.
Your treatment is covered up to 80% by health insurers (policy-dependent)
Indication
Both programmes are intended for adult patients (≥18 years) with treatment-resistant depressive disorder characterised by insufficient response to at least two antidepressants in adequate dosage and duration. Indication is established after screening and multidisciplinary consultation.
The programme with the possibility of racemic ketamine (intramuscular) is intended for patients in whom multiple treatment steps have not resulted in sustained recovery and for whom a short-term intensive trajectory is indicated.
For the programme with esketamine nasal spray (Spravato®) the following additional criteria apply:
- Insufficient response to at least one augmentation strategy
- Concurrent use of an oral antidepressant during esketamine treatment, as prescribed by the treating physician
- Prior authorization from the health insurer is required
Contra-indications
The main contraindications for participation in the program are:
A history of psychosis
Bipolar disorder type I
Acute suicidality
Acute suicidality
Severe cardiovascular disease
Pregnancy or breastfeeding
For the first time in my life, I can say that I experience calm and a sense of safety in my body, even when I am alone. Before, I only lived in my head, but now I live in the world."
Continue reading
The ketamine journeys have provided me with a wealth of wisdom and insights. Thanks to the ketamine, I was able to connect with deeply buried pain, but also with my true desires and abilities. Moreover, the ketamine has helped expand my ‘container,’ allowing me to dare to feel and connect—with my true self and with the world around me.
Together with my psychologist from Magnolia, Wiesje, I worked hard on the themes that emerged from my journeys. I have been able to create safety, both at home and in my relationships. For the first time in my life, I can say that I experience calm and a sense of safety in my body, even when I am alone. Additionally, I feel strength. I am better able to sense and protect my boundaries, which finally allows me to maintain a connection with myself. Slowly but surely, I am emerging from my ‘freeze’ mode; frozen energies (emotions) can now, little by little, leave my body. I can connect with my deepest desires and act from that place; step by step, I am letting go of pieces of my long-standing eating disorder, and the dysthymic disorder is making way for life energy, spontaneity, freedom, and self-compassion.
My heartfelt gratitude goes out to the Magnolia team and Menno Oosterhoff for the warm, loving, and skilled guidance throughout my journey. Movement has been sparked on so many levels—emotionally, physically, spiritually, relationally, and in my conscious “being.” The ketamine journeys turned out to be the missing link in my process toward further healing. Magnolia came into my life at exactly the right moment. Thank you for everything!
“Before, I only lived in my head, but now I live in the world.”
Differences between the programmes
Programme with the possibility of racemic ketamine (intramuscular)
- Short-term trajectory (approximately six weeks)
- Intensive psychotherapeutic guidance
- Possibility of additional non-reimbursed ketamine sessions
Aimed at facilitating a therapeutic breakthrough within a defined period.
Read more about this program ->
Esketamine Nasal Spray Program
- A personalized treatment program for treatment-resistant depression, in which the duration and intensity are determined individually based on treatment course and clinical judgment
- Esketamine nasal spray as an integral part of the treatment
- Phased initiation and tapering depending on clinical response
- Focused on gradual improvement, stabilization, and relapse prevention
Both trajectories are embedded in a broader treatment plan with medical supervision, structured evaluation and multidisciplinary consultation.
Read more about this program ->
Start your first treatment immediately after screening
Specialized medical treatment team
Safety and well-being
Insured care (policy-dependent)
Nature, tranquility and privacy
Screening and monitoring
Before treatment begins, an extensive screening takes place in which psychiatric history, previous treatment steps, somatic burden and possible contra-indications are carefully assessed.
During treatment:
- Treatment response is evaluated
- Side effects are monitored
- Indication and treatment strategy are adjusted where necessary
The referring clinician is involved in relevant feedback — with the patient’s consent.
Costs and reimbursement
Magnolia operates without contracts with health insurers. Both treatment programs therefore fall under out-of-network care.
The screening takes place within specialist mental healthcare (sGGZ) and is free of charge. The reimbursement the patient receives from their health insurer for the screening is paid to Magnolia. A referral to specialist mental healthcare (sGGZ) is required for participation.
The program involving racemic ketamine (intramuscular administration) is a short-term treatment trajectory of approximately six weeks. Total costs range between €7,000 and €8,700, depending on the involvement of a psychologist or psychotherapist and the exact duration of the program. The final out-of-pocket contribution depends on the patient’s insurance policy and reimbursement percentage. The use of racemic ketamine is priced at €175 per session and is not reimbursed. If the out-of-pocket contribution presents a barrier, solutions are always explored in consultation with the patient.
The program with esketamine nasal spray is tailored to the individual and has a variable duration, depending on treatment response and clinical judgment. The out-of-pocket contribution consists of:
- €50 per esketamine administration
- €50 per month for psychiatric consultation.
These amounts apply regardless of the reimbursement percentage of the health insurer. Based on approximately 20 treatments over a period of six months, this results in an average out-of-pocket contribution of around €215 per month. The esketamine nasal spray itself is — following approved authorization — fully reimbursed by the health insurer.
Within Magnolia’s treatment philosophy, psychotherapeutic support — preferably in the form of weekly sessions with a psychologist — is considered an important part of the treatment. This support can be added to the treatment program in consultation with the patient and involves additional costs.
The financial framework is discussed transparently with the patient prior to the start of treatment. If the out-of-pocket contribution presents a barrier, options are explored to determine what is appropriate in the individual situation.
Referral and collaboration
Referral can take place via:
- ZorgDomein
- Direct intercollegial contact with Magnolia Therapy
We value close collaboration with referring clinicians and welcome consultation regarding indication, patient suitability or individual cases.
Program for treatment-resistant depression
More information
For extensive documentation (inclusion and exclusion criteria, programme structure, safety protocols and cost information) you can contact our team.
We can send you the full referring clinicians’ brochure upon request or schedule a phone consultation.
[email protected]
085-212 77 36
Referral via ZorgDomein possible